Rituximab remains an important therapeutic option for patients with rheumatoid arthritis; however, clinical response remains heterogeneous, with only 30% of patients with an inadequate response to anti-TNF reported to have an ACR50 response at 6 months.6 The gene discussed is TNF; the disease is rheumatoid arthritis.